Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
45 filings of MEDANTA since November 2024; the newest 40 below.
board outcome 12, presentation 10, transcript 9, credit rating 5, results 4, scheme 3
| Filed | Type | Subject | |
|---|---|---|---|
| 14 Nov 2026 | presentation Acquisition, Capex, Results | Global Health Limited has informed the Exchange about Investor PresentationAI summaryGlobal Health Ltd (Medanta) filed an investor presentation for Analysts/Investors Meets scheduled on November 16, 17, 19 and 20, 2026, covering Q2 and H1 FY2027 performance. Q2 FY2027 revenue from operations was INR 14,690 million, up 33.6% y-o-y; Operating EBITDA was INR 3,701 million (margin 25.2% vs 21.0% in Q2 FY26); PAT was INR 2,191 million (margin 14.9% vs 14.4%). In-patient volumes grew 29.5% and out-patient volumes grew 37.9% y-o-y; ARPP was INR 2.06 lakh vs INR 2.01 lakh; ALOS was 2.89 days vs 3.06 days. Census bed capacity stood at 3,115 in Q2 FY27 vs 2,658 in Q2 FY26; 74 beds were added during the quarter. Ghaziabad land parcel of 2.61 acres was allotted in an e-auction for INR 1,658.2 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Nov 2026 | transcript Capex, Guidance, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryGlobal Health Limited (Medanta) filed the transcript of its Q2 FY27 and H1 FY27 earnings conference call held on November 4, 2026. Management reported Q2 FY27 consolidated revenue from operations of INR 14,690 million (up 34% YoY), operating EBITDA of INR 3,701 million (up 60% YoY, margin 25.2% vs 21%), and profit after tax of INR 2,191 million (up 38% YoY). Management said Medanta Noida (550 beds) achieved EBITDA breakeven in Q2 FY27, with revenue from operations of INR 1,059 million and operating EBITDA of INR 86 million. Management said the Board approved a 500-bed Ghaziabad hospital with total capex of approximately INR 1,000 crore, after the land was acquired through e-auction at INR 166 crore. Management said it plans a capex of over INR 6,000 crore over the next 4 to 5 years and a bed addition of about 3,450 beds over the next few years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2026 | presentation Capex, Legal, Results | Global Health Limited has informed the Exchange about Investor PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for Q2 and H1 FY2027 results (quarter ended September 30, 2026) on November 3, 2026. Q2 FY27 revenue from operations was INR 14,690 million, up 33.6% y-o-y; operating EBITDA was INR 3,701 million (margin 25.2%) versus 21.0% in Q2 FY26. Profit after tax was INR 2,191 million (margin 14.9%) versus INR 1,584 million in Q2 FY26. In-patient volume grew 29.5% and out-patient volume grew 37.9% y-o-y; census bed capacity stood at 3,115 beds. Management said the company added 74 beds in the quarter, onboarded 100+ doctors, and that Ghaziabad land of 2.61 acres was allotted in an e-auction for INR 1,658.2 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2026 | board outcome Capex, Results | Global Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryGlobal Health Limited (Medanta) board outcome dated November 03, 2026: approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with unmodified limited review reports from Walker Chandiok & Co LLP. Board approved a project budget of Rs. 997 crores (including cost of land) for construction of a 500-bedded hospital on a 10560.36 sq. meter land parcel allotted by UP Housing & Development Board (UPAVP) at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh. This is in continuation of an earlier intimation dated September 28, 2026 on the hospital project. Trading window will open after 48 hours from the declaration of the results. The board meeting commenced at 2:00 P.M. and concluded at 3:45 P.M. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | transcript Capex, Guidance, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryGlobal Health Limited (Medanta) filed the transcript of its Q1 FY27 earnings conference call held on July 31, 2026, for the quarter ended June 30, 2026. Management reported consolidated income of INR13,262 million (up 26% year-on-year) and reported EBITDA including Noida of INR3,153 million (up 23%, margin 23.8%); profit after tax was INR1,573 million versus INR1,590 million in Q1 FY26, which included a one-time exceptional income of INR196 million. Management said Medanta Noida's EBITDA loss narrowed to INR49 million from INR236 million in Q4 FY26, and that Noida is expected to reach EBITDA breakeven earlier than previously expected. Management said the Guwahati hospital has been revised to a 650-bed super specialty hospital with an estimated project cost of about INR9,700 million, and the announced expansion pipeline is about 3,350 additional beds. Management said it does not give margin guidance and that cash flow generation remains strong with low leverage. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2026 | presentation Results | Global Health Limited has informed the Exchange about Investor PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for the first quarter ended June 30, 2026 (Q1 FY2027), dated July 30, 2026. Total income was INR 13,262 million, up 26.2% y-o-y from INR 10,513 million in Q1 FY26. EBITDA ex-Noida was INR 3,201 million (margin 25.8%), up 23.9% y-o-y; reported EBITDA including Noida was INR 3,153 million (margin 23.8%), up 23.5% y-o-y. Profit after tax was INR 1,573 million (margin 11.9%), against INR 1,590 million in Q1 FY26, which included a non-recurring exceptional income of INR 196 million. Management said volume growth remained robust, with in-patients up 27.7% and out-patients up 34.5% y-o-y, and ARPOB up 5.5% y-o-y to INR 70,224. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2026 | board outcome Capex, Dividend / buy-back, Management change, Results | Global Health Limited has informed the Exchange regarding Outcome of Board Meeting held on July 30, 2026.AI summaryGlobal Health Limited (Medanta) board meeting held July 30, 2026 approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from Walker Chandiok & Co LLP enclosed. The board fixed Friday, August 14, 2026 as record date for final dividend of Rs. 0.50 per equity share for FY 2025-26, subject to shareholder approval at the 22nd AGM. The 22nd AGM is to be held on Wednesday, September 16, 2026 at 12:00 noon through VC/OAVM. Pradeep Kumar Singh was appointed Chief Digital Officer and a senior management personnel, effective July 30, 2026. The board approved a revised construction plan for the upcoming Guwahati hospital, increasing proposed bed capacity from 400 beds to 650 beds. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2026 | board outcome Capex, Dividend / buy-back, Management change, Results | Global Health Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryGlobal Health Limited (Medanta) board meeting outcome dated July 30, 2026: approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from Walker Chandiok & Co LLP enclosed. Board fixed August 14, 2026 as record date for final dividend of Rs. 0.50 per equity share for FY 2025-26, subject to shareholder approval at the 22nd AGM. 22nd AGM to be held on September 16, 2026 at 12:00 Noon via VC/OAVM. Board appointed Mr. Pradeep Kumar Singh as Chief Digital Officer and SMP, effective July 30, 2026. Board approved revised Guwahati hospital plan, increasing proposed bed capacity from 400 to 650 beds. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2026 | transcript Capex, Dividend / buy-back, Guidance, Results | Global Health Limited has informed the Exchange about Announcement under Regulation 30 of Listing regulations for Earning Call Transcript.AI summaryGlobal Health Ltd (Medanta) filed the transcript of its Q4 and FY26 earnings conference call held on May 15, 2026. Management said FY26 total income rose 20% year-on-year to INR 45,089 million and consolidated profit after tax rose 15.1% to INR 5,541 million; Q4 FY26 total income was INR 11,958 million, up 25%, with Q4 PAT of INR 1,417 million. Management announced a final dividend of INR 0.50 per share (25% of the INR 2 face value) recommended by the Board. Management said the Noida hospital (550 beds) recorded an FY26 EBITDA loss of INR 783 million, with the Q4 loss narrowing to INR 236 million. Management outlined a plan to add about 2,700 beds through five greenfield projects over 3 to 4 years, with total project capex of about INR 45,000 million over the next 5 years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2026 | presentation Acquisition, Capex, Results | Global Health Limited has informed the Exchange about Investor PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for Q4 and FY2026 results, dated 14 May 2026, under Regulation 30 of SEBI LODR. Consolidated bed count rose by 623 during FY2026, a 20.5% bed growth; Medanta Noida (382 operational beds, 14 OTs) was inaugurated on 27 November 2025. Ranchi new 110-bed unit was operationalized in July 2025; Patna added 131 beds; Guwahati 400-bed project approved by the board and land purchase completed in September 2025. Varanasi 400-bed hospital project approved by the board in March 2026 under a built-to-suit and lease arrangement. Takeover of an ~80-bed cancer hospital in Indore under a business transfer agreement in April 2026, to be operationalized in Q2 FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2026 | dividend Dividend / buy-back, Management change, Results | Global Health Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2026, recommended Final Dividend of Rs. 0.50 per equity share.AI summaryGlobal Health Limited (Medanta) board meeting outcome dated May 14, 2026: approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with unmodified auditor report from Walker Chandiok & Co LLP. Board recommended a final dividend of Rs. 0.50 per equity share (25%) on face value Rs. 2, subject to shareholder approval at the AGM; record date to be intimated separately. Appointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel, both as SMPs, effective May 14, 2026. Noted resignation of Ms. Richa Singh, an SMP, effective May 20, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 May 2026 | board outcome Dividend / buy-back, Management change, Results | Global Health Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryGlobal Health Limited (Medanta) board outcome dated May 14, 2026: approved audited standalone and consolidated results for Q4 and FY ended March 31, 2026, with unmodified auditor report from Walker Chandiok & Co LLP. Board recommended final dividend of Rs. 0.50 per equity share (25% on face value of Rs. 2), subject to AGM approval; record date to be intimated separately. Appointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel, both as SMPs, effective May 14, 2026. Noted resignation of Richa Singh, an SMP, effective May 20, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Apr 2026 | board outcome Acquisition, Capex | Global Health Limited has informed the Exchange regarding Outcome of Board Meeting held on April 27, 2026.AI summaryGlobal Health Limited (Medanta) board approved execution of a Business Transfer Agreement to acquire a 79-bed cancer care hospital in Indore, owned and operated by Asian Institute of Oncology Private Limited, along with assignment of the lease deed and a fresh lease for an additional 1,700 sqft. Consideration is Rs. 30 crores in cash; the target hospital's turnover for FY 2024-25 was Rs. 19.9 million, and the transaction is not a related party transaction. Acquisition is subject to statutory and customary approvals, mainly change of ownership; the BTA long stop date is September 30, 2026, though completion is expected well before that. Management stated the hospital is about 500 metres from Medanta's existing Indore facility and will add 79 beds, funded by internal accruals and debt. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | transcript Capex, Guidance, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryGlobal Health Limited (Medanta) filed the transcript of its Q3 FY26 earnings conference call held on February 5, 2026, covering the quarter and nine months ended December 31, 2025. Management reported Q3 FY26 total income of Rs.11,428 million, up 19% year-on-year, and consolidated profit after tax of Rs.950 million, or Rs.1,224 million excluding a one-time labour codes impact of Rs.366 million. Management said Medanta Noida, which began operations in September 2025, generated Rs.343 million revenue and an EBITDA loss of Rs.320 million in Q3, and that it expects the peak of Noida losses has been seen. Management reported EBITDA excluding Noida of Rs.2,814 million (25.4% margin), up 11%, and including Noida of Rs.2,494 million (21.8% margin). Management said bed capacity rose by 537 beds in the first nine months of FY26 and that 496 further beds are possible through brownfield expansion, with pipeline projects under way in Guwahati, Mumbai, South Delhi and Pitampura. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Feb 2026 | presentation Results | Global Health Limited has informed the Exchange about Investor PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for Q3 and 9M FY2026 results (quarter and nine months ended December 31, 2025). Q3 FY26 total income was INR 11,428 million, up 19.1% y-o-y; EBITDA ex-Noida was INR 2,814 million (margin 25.4%), up 10.9% y-o-y. Reported EBITDA was INR 2,494 million (margin 21.8%), down 1.7% y-o-y; Medanta Noida recorded an EBITDA loss of INR 320 million in the quarter. Reported PAT was INR 950 million (margin 8.3%); adjusted PAT was INR 1,224 million after a non-recurring exceptional item of INR 366 million from the new Labour Codes. Management said volume growth remained robust, with in-patients up 14.3% and out-patients up 19.5% y-o-y, ARPOB up 9.9% to INR 67,361, and 144 beds added in Q3 FY26 (537 in 9M FY26). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Feb 2026 | board outcome Management change, Results | Global Health Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryBoard of Global Health Limited (Medanta) approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with limited review reports from Walker Chandiok & Co LLP (Annexure A). Board approved appointment of Mr. Malik Mohd. Ashhab as Senior Management Personnel, designated Head-Diagnostic Services. Board recommended to shareholders, via postal ballot, re-appointment of Dr. Ravi Gupta and Mr. Rajan Bharti Mittal as Independent Directors for a second 5-year term w.e.f. July 08, 2026. Board recommended appointment of Ms. Shonan Purie Trehan as Non-Executive Non-Independent Director, liable to retire by rotation, w.e.f. March 13, 2026. Cut-off date for postal ballot is February 6, 2026; trading window opens after 48 hours from declaration of results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Dec 2025 | credit rating Rating | Global Health Limited has informed the Exchange about Credit Rating- RevisionAI summaryGlobal Health Limited (Medanta) filed an intimation under Regulation 30 of SEBI LODR regarding a revised credit rating letter from CRISIL Ratings dated December 16, 2025. Total bank loan facilities rated: Rs. 1,500 crore. Long-term rating upgraded to CRISIL AA/Stable from CRISIL AA-/Positive. Short-term rating CRISIL A1+ reaffirmed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | transcript Capex, Guidance, Management change, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryGlobal Health Limited (Medanta) filed the transcript of its Q2 FY26 earnings conference call held on November 10, 2025, for the quarter ended September 30, 2025. Consolidated total income was INR 11,189 million, up 15% from INR 9,748 million a year earlier; PAT was INR 1,584 million, up 21%, with PAT margin of 14.2%. EBITDA including Noida was INR 2,607 million, up 6% year-on-year, with margin of 23.3%; EBITDA excluding Noida grew 14% to INR 2,804 million (margin 25.2%). Management said Medanta Noida, its sixth hospital, began operations in September 2025 with 226 operational beds; in its first month it generated revenue of INR 39 million and an EBITDA loss of INR 197 million, in line with ramp-up expectations. Management said H1 FY26 capex was about INR 4,252 million and net cash surplus was INR 7,082 million at September 30, 2025, and approved a revised Mumbai (Oshiwara) project cost of INR 15,300 million for 750 beds. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | presentation Capex, Results | Global Health Limited has informed the Exchange about Investor PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for the Second Quarter and Half Year ended September 30, 2025 (Q2 and H1 FY2026), dated November 7, 2025. Consolidated total income for Q2 FY26 was INR 11,189 million, up 14.8% y-o-y from INR 9,748 million; PAT was INR 1,584 million, up 21.1% y-o-y, with PAT margin of 14.2%. EBITDA excluding Medanta Noida was INR 2,804 million (margin 25.2%), up 13.7% y-o-y; including Noida, EBITDA was INR 2,607 million (margin 23.3%), up 5.7% y-o-y. Medanta Noida commenced operations in September 2025 with revenue of INR 39 million and an EBITDA loss of INR 197 million in the quarter, per the presentation. Management said ARPOB grew 5.5% y-o-y to INR 65,570 and occupied bed days rose 7.7% y-o-y; international patient revenue rose 48.5% y-o-y to INR 762 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | board outcome Acquisition, Capex, Results | Global Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryGlobal Health Limited (Medanta) board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with limited review reports from Walker Chandiok & Co LLP. Standalone Q2 FY26 revenue from operations was Rs 9,264.28 million, against Rs 8,310.49 million in Q2 FY25 (restated); Q2 profit after tax was Rs 401.99 million. Standalone half-year (H1 FY26) revenue from operations was Rs 18,085.84 million and profit after tax was Rs 2,921.63 million (restated figures; the results reflect an NCLT-approved amalgamation of a wholly owned subsidiary, Medanta Holdings Private Limited, effective from April 1, 2024). The board approved increasing the proposed Mumbai hospital capacity from 500 beds to 750 beds after receipt of additional FSI approval from MHADA. The board approved acquisition of 30 residential flats near the proposed Mumbai hospital for up to Rs 85 crores, raising the total Mumbai project cost to Rs 1,530 crores from Rs 1,200 crores. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Oct 2025 | credit rating Rating | Global Health Limited has informed the Exchange about Credit RatingAI summaryGlobal Health Limited (Medanta) filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit rating from CRISIL Ratings. CRISIL Ratings issued a revised credit rating letter dated October 16, 2025, adding bank names to the company's facilities. Total bank loan facilities rated: Rs. 1500 crore, with long-term rating CRISIL AA-/Positive and short-term rating CRISIL A1+. Bank-wise annexure lists term loans (Rs. 610 crore proposed, Rs. 400 crore SBI, Rs. 100 crore ICICI Bank), and working capital facilities (Rs. 50 crore SBI, Rs. 150 crore HDFC Bank, Rs. 50 crore ICICI Bank, Rs. 140 crore YES Bank), with the letter's ratings applying to these. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 Sep 2025 | results Results | The Exchange had sought clarification from Global Health Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company AI summaryDeclaration under Regulation 33(3)(d) of SEBI LODR confirming that the Statutory Auditors, M/s Walker Chandiok & Co. LLP, issued unmodified and unqualified audit reports. The audit reports cover the Annual Audited Standalone and Consolidated Financial Results for the financial year ended March 31, 2025. The declaration refers to an earlier intimation dated May 15, 2025 on the outcome of the board meeting. The letter is dated May 23, 2025, though the filing date is listed as September 22, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 Aug 2025 | transcript Capex, Management change, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryGlobal Health Limited (Medanta) filed the transcript of its Q1 FY26 earnings conference call held on August 08, 2025. Management (Group CEO Pankaj Sahni) said Q1 FY26 total income was INR10,513 million, up 19% year-on-year, and EBITDA was INR2,553 million, up 23%, with a 24.3% margin. Profit after tax was INR1,590 million, up 50%, including a non-recurring exceptional income of INR196 million. Inpatient volumes rose 14% and outpatient volumes 13% year-on-year; ARPOB was INR66,584 versus INR64,035 a year earlier. Management said the 550-bed Medanta Noida facility is expected to operate in the coming weeks, a 110-bed Ranchi hospital was operationalised in July 2025, and the pipeline now includes 2,000 beds over three to four years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Aug 2025 | presentation Capex, Results | Global Health Limited has informed the Exchange about PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for the quarter ended June 30, 2025 (Q1 FY2026), dated August 7, 2025. Consolidated Total Income was INR 10,513 million, up 19.1% year-on-year; EBITDA was INR 2,553 million (up 22.6%), with EBITDA margin of 24.3% versus 23.6% in Q1 FY25. Profit After Tax was INR 1,590 million, up 49.6%, with PAT margin of 15.1%; management said PAT includes non-recurring exceptional income of INR 196 million from reversal of potential EPCG interest liability. Management said occupied bed days rose 13.3% and ARPOB grew 4.0% to INR 66,584; 20 new beds were added at Patna and a 110-bed hospital in Ranchi was operationalized in July 2025. Management reported 150+ doctors onboarded in the quarter and International Patients Revenue up 33.8% to INR 636 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Aug 2025 | board outcome Dividend / buy-back, Management change, Results | Global Health Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryGlobal Health Limited (Medanta) board outcome dated August 7, 2025: approved unaudited standalone and consolidated results for the quarter ended June 30, 2025, with limited review reports from Walker Chandiok & Co LLP. Board fixed August 22, 2025 as record date for final dividend of Rs. 0.50 per equity share for FY 2024-25, subject to shareholder approval at the 21st AGM on September 19, 2025. Board recommended re-appointment of Dr. Naresh Trehan as Chairman and Managing Director for 5 years w.e.f. August 1, 2026, and of independent directors Vikram Singh Mehta (w.e.f. January 25, 2026) and Hari Shanker Bhartia (w.e.f. March 23, 2026) for second 5-year terms, all subject to shareholder approval. Board recommended appointment of MAKS & Co. as Secretarial Auditors for five years starting FY 2025-26, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jun 2025 | results | The Exchange has sought clarification from Global Health Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company | |
| 21 May 2025 | transcript Acquisition, Capex, Dividend / buy-back, Guidance, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryMedanta (Global Health Ltd) filed the transcript of its Q4 and FY25 earnings conference call held on May 16, 2025. FY25 total consolidated income was INR 37,714 million (up 13% YoY); EBITDA INR 9,562 million (up 9%, margin 25.4%); reported PAT INR 4,813 million after one-time exceptional expenses of INR 499 million from the merger of MHPL; adjusted PAT INR 5,186 million (up 9%). Management said the Board recommended a first-ever dividend of 25%, amounting to INR 0.5 per share. Management said capex of INR 6,449 million was incurred in FY25 and plans to add about 3,000 beds over 3 to 4 years with an earmarked outlay of around INR 4,000 crores, funded through internal accruals and debt. Q4 FY25 total income was INR 9,542 million (up 14% YoY) and EBITDA INR 2,476 million (up 20%, margin 26.0%). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 May 2025 | presentation Acquisition, Capex, Guidance, Results | Global Health Limited has informed the Exchange about PresentationAI summaryGlobal Health Limited (Medanta) filed a revised investor presentation for Q4 and FY2025 results, dated 15 May 2025, under Regulation 30 of SEBI LODR, with the filing dated 16 May 2025. The company revised slides 13, 19, 22 and 26 and restated Matured and Developing hospital numbers due to the merger of MHPL (Lucknow Unit) with GHL, with intercompany transactions eliminated. The presentation states the network has 5 operating multi-speciality hospitals and 6 upcoming hospitals, with 3,042 total beds. Management reports 219 beds added during FY2025 (7.8% bed growth), 119+ doctors onboarded in FY25, and 2 new labs bringing the total to 11. Management highlights planned capacity of about 3,000 beds, a Ranchi 110-bed hospital expected to operationalise in Q1 FY26, and Noida's 300 beds expected by Q2 FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2025 | presentation Capex, Management change, Results | Global Health Limited has informed the Exchange about PresentationAI summaryGlobal Health Limited (Medanta) filed its investor presentation for the fourth quarter and financial year ended March 31, 2025. The presentation covers FY2025 year-at-a-glance, FY2025 and Q4 FY2025 performance updates, project updates and capex plan. Management reports 219 beds added during FY2025, a 7.8% bed growth on a consolidated basis, and 119+ doctors onboarded in FY25. Planned projects include a 550-bed Noida hospital (300 beds expected operational by Q2 FY26) and a 400-bed Guwahati hospital approved by the Board. The presentation does not include the financial figures in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2025 | dividend Dividend / buy-back, Management change, Results | Global Health Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs. 0.50 per equity share.AI summaryGlobal Health Limited (Medanta) filed the outcome of its May 15, 2025 board meeting, which approved audited standalone and consolidated financial results for Q4 and the year ended March 31, 2025. The board recommended a final dividend of Rs. 0.50 per equity share (25% on face value of Rs. 2), subject to shareholder approval at the ensuing AGM; the record date will be intimated separately. The board approved the appointment of Dr. Pankaj Dhamija as Senior Management Personnel, designated Hospital Director – Gurugram Unit, on the recommendation of the Nomination and Remuneration Committee. The auditor's report from Walker Chandiok & Co LLP is unmodified; it includes an emphasis of matter on the amalgamation of wholly-owned subsidiary Medanta Holdings Private Limited, approved by NCLT on February 20, 2025, with effect from April 1, 2024. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2025 | board outcome Acquisition, Dividend / buy-back, Management change, Results | Global Health Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.AI summaryGlobal Health Limited (Medanta) filed the outcome of its board meeting held May 15, 2025, approving audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2025. The board recommended a final dividend of Rs. 0.50 per equity share (25% on face value of Rs. 2), subject to shareholder approval at the ensuing AGM; the record date will be intimated separately. The board approved the appointment of Dr. Pankaj Dhamija as Senior Management Personnel, designated Hospital Director – Gurugram Unit, on the recommendation of the Nomination and Remuneration Committee. The audit reports from Walker Chandiok & Co LLP include an emphasis of matter (not a modification of opinion) on a scheme of amalgamation of erstwhile wholly-owned subsidiary Medanta Holdings Private Limited, approved by NCLT on February 20, 2025, with appointed date April 1, 2024. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Apr 2025 | board outcome Acquisition, Capex | Global Health Limited has informed the Exchange regarding Outcome of Board Meeting held on April 28, 2025.AI summaryGlobal Health Limited (Medanta) board approved on April 28, 2025 the purchase of a 3-acre land parcel from Assam Electricity Grid Corporation Limited (AEGCL) at Sarusajai Electrical Sub-station, Guwahati, Assam, for Rs. 30 crores. The land is to be used for a 400+ bedded super speciality hospital with an estimated project cost of Rs. 510 crores, subject to customary and statutory approvals. Capacity is to be added over the next 3-4 years in a phased manner, funded from internal accruals. Medanta had existing capacity of 3,042 beds as on March 31, 2025. The board meeting ran from 2.00 P.M. to 2.35 P.M. (IST). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Apr 2025 | board outcome Dividend / buy-back | Global Health Limited has informed the Exchange regarding Nomination and Remuneration Committee meeting held on April 08, 2025.AI summaryGlobal Health Limited (Medanta) intimated to BSE and NSE that its Nomination and Remuneration Committee, meeting held on April 08, 2025, approved the grant of 5,85,500 options to eligible employees under Part A of the GHL LTIP 2024 Plan (ESOS). The Committee also approved the offer of 2,03,000 shares to eligible employees under Part B of the plan (ESPS). Exercise price is Rs. 2 per share for both the options and the shares offered; each option results in allotment of one equity share of Rs. 2 each. A total of 60 employees are covered under the option grant and 21 under the share offer, including employees of subsidiaries. Each offer must be exercised on or before July 31, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Mar 2025 | credit rating Rating | Global Health Limited has informed the Exchange about Credit Rating- RevisionAI summaryIntimation to BSE and NSE of a credit rating from CRISIL Ratings for Global Health Limited (Medanta), dated March 18, 2025. Total bank loan facilities rated enhanced to Rs 1,500 crore from Rs 950 crore, following the merger of wholly owned subsidiary Medanta Holdings Private Limited with the company. CRISIL reaffirmed long-term rating at CRISIL AA-/Positive and short-term rating at CRISIL A1+. The rating rationale is dated March 17, 2025, and the filing attaches the rating letter and rationale. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Mar 2025 | scheme Acquisition, Legal | Global Health Limited has informed the Exchange about Amalgamation/MergerAI summaryIntimation under Regulation 30 of SEBI LODR that the NCLT (New Delhi Bench-V) approved Scheme of Amalgamation between Medanta Holdings Private Limited (wholly-owned subsidiary) and Global Health Limited has been filed with the Registrar of Companies, NCT of Delhi & Haryana on March 01, 2025. Once formally noted by the ROC, the Scheme becomes effective and Medanta Holdings Private Limited will stand dissolved and cease to be a wholly-owned subsidiary with effect from March 01, 2025. The Appointed Date of the Scheme is April 01, 2024. This is in furtherance of an earlier intimation dated February 21, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Feb 2025 | scheme Acquisition, Legal | Global Health Limited has informed the Exchange about Amalgamation/MergerAI summaryGlobal Health Limited (Medanta) filed intimation under Regulation 30 of SEBI LODR regarding the final order of the NCLT New Delhi Bench (order dated 20.02.2025). The NCLT sanctioned the Scheme of Amalgamation between Medanta Holdings Private Limited (wholly-owned subsidiary, transferor) and Global Health Limited (transferee), under Sections 230-232 of the Companies Act, 2013. The Scheme will come into effect once the certified copy of the NCLT order is filed with the respective Registrar of Companies by the transferor and transferee companies. The company stated that a copy of the order is available on its website. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Feb 2025 | scheme Acquisition, Legal | Global Health Limited has informed the Exchange about Amalgamation/MergerAI summaryThe company filed an intimation under Regulation 30 of SEBI LODR regarding the final order of the Hon'ble National Company Law Tribunal, New Delhi Bench. The NCLT approved the Scheme of Amalgamation between Medanta Holdings Private Limited (a wholly-owned subsidiary) and Global Health Limited, under Sections 230 to 232 of the Companies Act, 2013. The final order has not yet been uploaded on the NCLT website at the time of filing. The Scheme will come into effect once the certified copy of the NCLT order is filed with the respective Registrar of Companies by the transferor and transferee companies. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Feb 2025 | results Results | Integrated filing (Financials) for the Quarter and Nine Months ended on December 31, 2025.AI summaryGlobal Health Limited (Medanta) filed its Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024, under SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185. The filing includes the Independent Auditor's Review Report by Walker Chandiok & Co LLP on consolidated unaudited quarterly and year-to-date results, dated February 4, 2025, with an unmodified conclusion that nothing came to the auditor's attention indicating material misstatement. The review covers the Holding Company and five subsidiaries, including Medanta Holdings Private Limited and GHL Hospital Limited. The company states the filing is also available on its investor relations website. The pages provided do not include the financial figures (revenue, profit or dividend). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | transcript Capex, Guidance, Management change, Results | Global Health Limited has informed the Exchange about TranscriptAI summaryGlobal Health Ltd (Medanta) filed the transcript of its Q3 and 9M FY25 earnings conference call held on February 5, 2025. Management reported Q3 FY25 total income of Rs. 9,595 million (up 12% from Rs. 8,545 million), EBITDA of Rs. 2,538 million (up 8%, margin 27.5%) and profit after tax of Rs. 1,429 million (up 16%, PAT margin 14.9%). Inpatient volumes rose 13% year-on-year to 44,856 and outpatient volumes rose 9%; ARPOB was Rs. 61,307 versus Rs. 60,571, a 1.3% rise attributed to case mix. Management said the board approved a long-term lease for a newly built 110-bed hospital in Ranchi, and that the 550-bed Noida hospital is expected to commence operations within about six months. Management said it is "very bullish" on the Lucknow and Patna units and expects occupied bed days to keep increasing, while cautioning against reading occupancy percentage in absolute terms because bed additions change the denominator. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2025 | credit rating Capex, Rating | Global Health Limited has informed the Exchange about Credit Rating- OthersAI summaryMedanta (Global Health Limited) filed an intimation under Regulation 30 on credit rating dated February 5, 2025. CRISIL Ratings reaffirmed long-term rating at CRISIL AA-/Positive and short-term rating at CRISIL A1+. Total rated bank loan facilities increased to Rs. 950 crore from Rs. 500 crore. The facilities include a term loan of Rs. 400 crore from SBI (earlier Rs. 340 crore), working capital facilities from ICICI Bank, HDFC Bank and Yes Bank of Rs. 50 crore, Rs. 50 crore and Rs. 60 crore, and a new proposed term loan of Rs. 390 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.